Aptamers: Cutting edge of cancer therapies

Shigdar, Sarah; Schrand, Brett; Giangrande, Paloma H.; Franciscis, Vittorio de

doi:10.1016/j.ymthe.2021.06.010

Cited by 70 publications

(49 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The improved tumor accumulation of hNPs than free dye was probably due to the increased size, which diminished renal clearance and leaved more drugs available in blood circulation. The targeting ability to tumor could be achieved by conjugating antibodies or aptamers that can selectively bind to tumor [ 39 – 42 ]. Collectively, these results demonstrated that hNPs greatly increased drug accumulation in the tumor.…”

Section: Resultsmentioning

confidence: 99%

Doxorubicin and CpG loaded liposomal spherical nucleic acid for enhanced Cancer treatment

Deng

et al. 2022

J Nanobiotechnol

View full text Add to dashboard Cite

Chemotherapeutics that can trigger immunogenic cell death (ICD) and release tumor-specific antigens are effective on treating a variety of cancers. The codelivery of chemotherapeutics with adjuvants is a promising strategy to achieve synergistic therapeutic effect. However, low drug loading and complicated preparation of current delivery systems lead to carrier-associated toxicity and immunogenicity. Herein, we developed a facile approach to construct liposomal spherical nucleic acids (SNA) by the self-assembly of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)-doxorubicin conjugate and DOPE-matrix metalloproteinases-9 (MMP-9) responsive peptide-CpG conjugate (DOPE-MMP-CpG). Liposomal SNAs efficiently co-delivered DOX and CpG into tumors and released the two drugs upon biological stimuli of MMP-9 enzyme in tumor microenvironment (TME) and high concentration of endogenous glutathione in tumor cells. We demonstrated that liposomal SNA enhanced activation of dendritic cells (DCs), promoted expansion of CD8+ and CD4+ T cells in both tumors and spleen, inhibited tumor growth, and extended animal survival. This work provided a simple strategy of delivering chemotherapeutics and adjuvants to tumors with synergistic therapeutic effect and reduced side effect. Graphical Abstract

show abstract

Section: Resultsmentioning

confidence: 99%

Doxorubicin and CpG loaded liposomal spherical nucleic acid for enhanced Cancer treatment

Deng

et al. 2022

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…They have a specific binding ability to cancer-related biomarkers and cancer cells by folding into well-defined three-dimensional structures (Huang et al., 2021 ) and thus provide a promising way to deliver imaging agents and drugs to tumors. Furthermore, the fabrication of aptamer is executed out of the biological systems, reducing the risk of bacterial or viral contaminations (Huang et al., 2021 ; Shigdar et al., 2021 ). To date, isolation of various aptamers has been accomplished to specifically target substances in cancer cells, including mucin 1 (MUC1), epithelial cell adhesion molecule (EpCAM), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), nuclear factor-kB (NF-kB), programmed death-ligand 1(PDL1), and prostate-specific membrane antigen (PSMA) (Hashemi et al., 2020 ).…”

Section: Approaches For Target-specific Drug Deliverymentioning

confidence: 99%

Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems

et al. 2022

View full text Add to dashboard Cite

Conventional chemotherapy lacking target selectivity often leads to severe side effects, limiting the effectiveness of chemotherapy. Therefore, drug delivery systems ensuring both selective drug release and efficient intracellular uptake at the target sites are highly demanded in chemotherapy to improve the quality of life of patients with low toxicity. One of the effective approaches for tumor-selective drug delivery is the adoption of functional ligands that can interact with specific receptors overexpressed in malignant cancer cells. Various functional ligands including folic acid, hyaluronic acid, transferrin, peptides, and antibodies, have been extensively explored to develop tumor-selective drug delivery systems. Furthermore, cell-penetrating peptides or ligands for tight junction opening are also actively pursued to improve the intracellular trafficking of anticancer drugs. Sometimes, multiple ligands with different roles are used in combination to enhance the cellular uptake as well as target selectivity of anticancer drugs. In this review, the current status of various functional ligands applicable to improve the effectiveness of cancer chemotherapy is overviewed with a focus on their roles, characteristics, and preclinical/clinical applications.

show abstract

“… 5 , 6 The binding of baicalein to TLR4 that inhibits the HIF‐1α/VEGF signaling pathway holds a promising therapy for metastatic CRC treatment. In the further, we would use target delivery system such as nanoparticles 7 or aptamers 8 to deliver baicalein to the tumor site that can further enhance its anti‐CRC effect.…”

Section: Figurementioning

confidence: 99%

Baicalein is a novel TLR4‐targeting therapeutics agent that inhibits TLR4/HIF‐1α/VEGF signaling pathway in colorectal cancer

Chen

Zhong

Tan

et al. 2021

Clinical & Translational Med

View full text Add to dashboard Cite

Aptamers: Cutting edge of cancer therapies

Cited by 70 publications

References 142 publications

Doxorubicin and CpG loaded liposomal spherical nucleic acid for enhanced Cancer treatment

Doxorubicin and CpG loaded liposomal spherical nucleic acid for enhanced Cancer treatment

Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems

Baicalein is a novel TLR4‐targeting therapeutics agent that inhibits TLR4/HIF‐1α/VEGF signaling pathway in colorectal cancer

Contact Info

Product

Resources

About